Physician profile
Abha Rani
NPI 1093781056
$5,529.06
in general payments reported to CMS, 2019-2025
24 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $333 · 2021: $1,081 · 2022: $1,249 · 2023: $682 · 2024: $288 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,852.10 | 2019-2025 | |
| Janssen Biotech, INC. | $995.67 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $491.75 | 2019-2023 | Entyvio, Gattex |
| Pfizer INC. | $362.53 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.21 | 2019-2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $249.98 | 2019-2021 | |
| Genzyme Corporation | $152.50 | 2023-2024 | |
| Celgene Corporation | $150.04 | 2021-2023 | Zeposia |
| Novo Nordisk INC | $124.99 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $119.73 | 2021 | |
| Ironwood Pharmaceuticals, INC | $102.21 | 2019-2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $101.28 | 2020-2023 | Ocaliva |
| Braintree Laboratories, INC. | $93.36 | 2019-2022 | |
| Ucb, INC. | $87.52 | 2019 | |
| Ardelyx, INC. | $69.32 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.78 | 2021-2022 | |
| Daiichi Sankyo INC. | $64.51 | 2019-2022 | |
| Cook Medical LLC | $42.64 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $39.15 | 2019 | |
| Ferring Pharmaceuticals INC. | $29.49 | 2019-2021 | |
| Redhill Biopharma INC. | $21.06 | 2021 | |
| Qol Medical, LLC | $17.77 | 2021 | |
| Medtronic, INC. | $17.63 | 2025 | Venaseal |
| Endo Pharmaceuticals INC. | $13.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abha Rani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.